Other promising preclinical results with CAR-T cells have been achieved by targeting IGF1R and receptor tyrosine kinase-like orphan receptor 1 (ROR1), both of which are expressed across many sarcoma cell lines, including RMS. This evidence concerns the gene ROR1 and sarcoma.